Healthcare Industry News: Mylan
News Release - February 25, 2008
Mylan Announces Appointment of Eric M. Leeds as Senior Vice President and Head of Global Investor RelationsPITTSBURGH, Feb. 25 (HSMN NewsFeed) -- Mylan Inc. (NYSE: MYL ) today announced the appointment of Eric M. Leeds as Senior Vice President and Head of Global Investor Relations. Mr. Leeds brings to Mylan more than 20 years of capital markets experience. He most recently served as Senior Vice President and head of investor relations of NYSE-listed Primedia Inc., a Kohlberg Kravis Roberts (KKR) leveraged build up of 166 media acquisitions. While at Primedia, Mr. Leeds broadened and deepened investor awareness, interest and support through constant change, including 18 acquisitions, the sale or shut-down of 25 businesses and refinancings of term loans, indentures and preferred stock.
Prior to joining Primedia, Mr. Leeds was Executive Director of investor relations consultancy G. A. Kraut Company Inc., where he was head of investor relations simultaneously for three public companies majority held by John W. Kluge: Metromedia International Group, Metromedia Fiber Network and Big City Radio. Mr. Leeds was investor relations counsel to companies in all industries and geographies, including Accor, Boeing, British Telecom, Georgia-Pacific, Honeywell, Primedia, Lockheed Martin, Monsanto, Schlumberger, Sprint and Wachovia.
Mr. Leeds began his career in 1986 as a securities analyst at Lehman Brothers, working for an original member of the Buffett Partnership (now Berkshire Hathaway). He then served as an institutional investor at Chemical Bank Asset Management and Republic Bank Asset Management, where he was a member of their investment committee.
Mylan Vice Chairman and CEO Robert J. Coury said: "As a significantly larger, global company, we recognize the importance of best-in-class communications and transparency and are pleased that Eric has joined our executive team to further strengthen our communications with the investment community. Eric's strong financial background, combined with his international experience, knowledge of M&A and leverage, and in-depth understanding of the investment community will be invaluable in helping Mylan continue to grow its businesses and leadership positions around the world."
Mr. Leeds said: "I am honored to join Mylan at a time when the Company is developing and evolving so dramatically. This is a great opportunity for me to work with an extraordinary global management team that has demonstrated its ability to execute on its vision. I look forward to helping ensure that Mylan's investor program appropriately reflects its position as one of the leading quality generic pharmaceutical companies in the world."
Mr. Leeds earned a bachelor's of science in finance from New York University's Stern School of Business with additional education at the New York Institute of Finance and the American Management Association. He served on Standard & Poor's Institutional Market Services Advisory Council and was a founding board member of Institutional Investor Magazine's Journal of Strategic Investor Relations.
Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient (API) manufacturers in the world. Dey, L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas. For more information about Mylan, please visit www.Mylan.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsMylan and Lupin Receive European Marketing Authorization for Nepexto(R), Biosimilar Etanercept
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Bevacizumab for Review
Mylan and Pfizer Announce Appointment of Viatris Chief Financial Officer